Valeant Pharmaceuticals to provide update amid swirling controversy

MONTREAL – Valeant Pharmaceuticals will provide an update today on its latest plans to address concerns that have battered Canada’s largest drugmaker, including how it intends to replace U.S. mail-order pharmacy partner Philidor Rx Services.

Chairman and CEO Michael Pearson along with other top officials are also expected to discuss the company’s operations in its third conference call in less than a month.

Get weekly money news

Get expert insights, Q&A on markets, housing, inflation, and personal finance information delivered to you every Saturday.

Sign up for weekly money newsletter Get Started

By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy.

The Quebec-based company’s shares have plunged as a result of intense scrutiny about its business practices, including big price hikes for some of its products and its relationship with certain specialty pharmaceutical companies.

Shares have fallen about 70 per cent since August.

The U.S. Senate has launched an investigation into drug pricing, which includes Valeant, and the company has also received multiple subpoenas from federal prosecutors.